ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2555

Efficacy and Safety of Conventional and Targeted Synthetic Disease-Modifying Antirheumatic Drugs As Well As Glucocorticoids: A Systematic Literature Review Informing the 2016 Update of the Eular Recommendations for the Management of Rheumatoid Arthritis

Katerina Chatzidionysiou1, Sharzad Emamikia2, Jackie L. Nam3, Sofia Ramiro4, Josef Smolen5, Désirée van der Heijde6, Maxime Dougados7, Johannes WJ Bijlsma8, Gerd Burmester9, Marieke Scholte-Voshaar10, Ronald van Vollenhoven11,12 and Robert Landewé13, 1Karolinska Institute, Stockholm, Sweden, 2Department of Medicine, Karolinska Institute, Stockholm, Sweden, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4Leiden University Medical Center, Leiden, Netherlands, 5Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 6Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 7Paris Descartes University, Paris, France, 8Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 9Charité University Hospital, Berlin, Germany, 10EULAR Standing Committee of People with Arthritis/Rheumatism in Europe, Zurich, Switzerland, 11Amsterdam Rheumatology Center, Amsterdam, Netherlands, 12Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, 13Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: DMARDs, glucocorticoids, Janus kinase (JAK), rheumatoid arthritis (RA) and treatment guidlelines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: To inform the task force for the 2016 update of the EULAR recommendations for the management of RA on the evidence regarding the efficacy and safety of glucocorticoids (GCs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and targeted synthetic DMARDs (tsDMARDs) in RA by performing a systematic literature review (SLR). <> 

Methods: A SLR update using PubMed, Embase and the Cochrane library was performed (2013 – 2016) to assess the efficacy and safety of GCs, csDMARDs (as monotherapy or combination therapy) and tsDMARDs (tofacitinib and baricitinib) in randomized clinical trials. Meta-analysis was performed when possible. Risk of bias (RoB) was assessed using the Cochrane Collaboration tool.

Results: With regard to GCs, among 348 hits 5 studies were included in the analysis (table 1). Even patients without poor prognostic factors benefit from the addition of GCs to methotrexate (MTX). Lower doses of GCs seem to be as effective as higher doses. Long-term results of the CAMERA II trial showed increased cardiovascular risk for the early RA patients treated for at least 2 years with 10mg/d prednisone (not included in the table). With regard to csDMARDs, among 518 hits 2 new studies comparing MTX monotherapy with MTX in combination with another csDMARD without differences in GCs usage were identified. The tREACH trial, which used tight-control principles, reported a statistically significant benefit of combination therapy over monotherapy at 3 months that had disappeared at 12 months (disease activity, functional ability and radiographic progression) (table 2). In addition, more medication adjustments were needed in the combination group. In the CareRA trial combination with other csDMARDs was not superior to methotrexate monotherapy in early RA and monotherapy was better tolerated. With regard to tofacitinib (n=7) and baricitinib (n=9) RCTs had been meta-analysed showing that both are more effective than placebo on background MTX or de novo MTX (MTX-naïve) in different patient populations (MTX-naïve, csDMARD and bDMARD inadequate responders) with a pooled OR (95% CI) for ACR20 response for tofa and bari vs placebo of 3.1 (2.0-4.7) and 3.6 (2.4-5.5), respectively.

Conclusion: New evidence on the efficacy and safety of DMARDs in RA confirmed the benefit of the addition of GCs to csDMARDs in early RA but pointed to long-term cardiovascular risk. MTX monotherapy is as effective as MTX in combination with csDMARDs but better tolerated. Tofacitinib and baricitinib are effective tsDMARDs in various RA populations.

 


Disclosure: K. Chatzidionysiou, None; S. Emamikia, None; J. L. Nam, None; S. Ramiro, None; J. Smolen, AbbVie, 2,AbbVie, 5; D. van der Heijde, AbbVie, Amgen, Astellas, AstraZeneca, BMS, Celgene, Daiichi, Eli-Lilly, Galapagos, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, UCB, 5,Director of Imaging Rheumatology bv, 3; M. Dougados, None; J. W. Bijlsma, None; G. Burmester, UCB, 2,AbbVie, BMS, Hexal, Janssen Pharmaceutica Product, L.P., Lilly, MSD, MedImmune, Novartis Pharmaceutical Corporation, Pfizer Inc, Roche Pharmaceuticals, 5,AbbVie, BMS, Hexal, MSD, Novartis Pharmaceutical Corporation, Pfizer Inc, Roche Pharmaceuticals, 8; M. Scholte-Voshaar, None; R. van Vollenhoven, AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Roche, UCB Pharma, 2,AbbVie, Biotest, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Eli-Lilly, Merck, Pfizer, Roche, UCB Pharma, Vertex, 5; R. Landewé, None.

To cite this abstract in AMA style:

Chatzidionysiou K, Emamikia S, Nam JL, Ramiro S, Smolen J, van der Heijde D, Dougados M, Bijlsma JW, Burmester G, Scholte-Voshaar M, van Vollenhoven R, Landewé R. Efficacy and Safety of Conventional and Targeted Synthetic Disease-Modifying Antirheumatic Drugs As Well As Glucocorticoids: A Systematic Literature Review Informing the 2016 Update of the Eular Recommendations for the Management of Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/efficacy-and-safety-of-conventional-and-targeted-synthetic-disease-modifying-antirheumatic-drugs-as-well-as-glucocorticoids-a-systematic-literature-review-informing-the-2016-update-of-the-eular/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-conventional-and-targeted-synthetic-disease-modifying-antirheumatic-drugs-as-well-as-glucocorticoids-a-systematic-literature-review-informing-the-2016-update-of-the-eular/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology